Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma

Number of Participants with Adverse Events Related to Hepatic Failure, Hepatic Dysfunction, and Pancreatitis

An adverse event (AE) is any untoward or undesirable medical occurrence in a participant linked in time with the use of a pharmaceutical/ medicinal product. They are not limited to the events with clear causal relationship with treatment with concerned drug. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

Time frame: Up to 12 months

Number of Participants with Serious Adverse Events

A serious AE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.

Time frame: Up to 12 months

Number of Participants with Adverse Events Leading to Permanent Treatment Discontinuation with Cabozantinib Tablets

Time frame: Up to 12 months

Number of Participants with Grade 3 or higher Adverse Events

Severity grade is defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

Time frame: Up to 12 months